Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene

被引:40
作者
Iavarone, C
Acunzo, M
Carlomagno, F
Catania, A
Melillo, RM
Carlomagno, SM
Santoro, M
Chiariello, M
机构
[1] CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy
关键词
D O I
10.1074/jbc.M513397200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitogen-activated protein (MAP) kinases have a central role in several biological functions, including cell adhesion and spreading, chemotaxis, cell cycle progression, differentiation, and apoptosis. Extracellular signal- regulated kinase 8 (Erk8) is a large MAP kinase whose activity is controlled by serum and the c-Src non-receptor tyrosine kinase. Here, we show that RET/PTC3, an activated form of the RET proto-oncogene, was able to activate Erk8, and we demonstrate that such MAP kinase participated in RET/PTC3-dependent stimulation of the c-jun promoter. By using RET/PTC3 molecules mutated in specific tyrosine autophosphorylation sites, we characterized Tyr(981), a known binding site for c-Src, as a major determinant of RET/PTC3-induced Erk8 activation, although, surprisingly, the underlying mechanism did not strictly depend on the activity of Src. In contrast, we present evidence that RET/PTC3 acts on Erk8 through Tyr(981)-mediated activation of c-Abl. Furthermore, we localized the region responsible for the modulation of Erk8 activity by the RET/PTC3 and Abl oncogenes in the Erk8 C-terminal domain. Altogether, these results support a role for Erk8 as a novel effector of RET/PTC3 and, therefore, RET biological functions.
引用
收藏
页码:10567 / 10576
页数:10
相关论文
共 32 条
[1]   ERK-8, a new member of the mitogen-activated protein kinase family [J].
Abe, MK ;
Saelzler, MP ;
Espinosa, R ;
Kahle, KT ;
Hershenson, MB ;
Le Beau, MM ;
Rosner, MR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :16733-16743
[2]   ERK7 is an autoactivated member of the MAPK family [J].
Abe, MK ;
Kahle, KT ;
Saelzler, MP ;
Orth, K ;
Dixon, JE ;
Rosner, MR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (24) :21272-21279
[3]   The GDNF family: Signalling, biological functions and therapeutic value [J].
Airaksinen, MS ;
Saarma, M .
NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) :383-394
[4]  
Borrello MG, 1996, MOL CELL BIOL, V16, P2151
[5]   The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling [J].
Buschbeck, M ;
Ullrich, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (04) :2659-2667
[6]   Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors [J].
Carlomagno, F ;
Guida, T ;
Anaganti, S ;
Vecchio, G ;
Fusco, A ;
Ryan, AJ ;
Billaud, M ;
Santoro, M .
ONCOGENE, 2004, 23 (36) :6056-6063
[7]  
Carlomagno F, 2002, CANCER RES, V62, P1077
[8]   Molecular heterogeneity of RET loss of function in Hirschsprung's disease [J].
Carlomagno, F ;
DeVita, G ;
Berlingieri, MT ;
deFranciscis, V ;
Melillo, RM ;
Colantuoni, V ;
Kraus, MH ;
DiFiore, PP ;
Fusco, A ;
Santoro, M .
EMBO JOURNAL, 1996, 15 (11) :2717-2725
[9]   Multiple mitogen-activated protein kinase signaling pathways connect the Cot oncoprotein to the c-jun promoter and to cellular transformation [J].
Chiariello, M ;
Marinissen, MJ ;
Gutkind, JS .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (05) :1747-1758
[10]   Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs):: evidence for a divergence of the ERKs and JNKs pathways induced by Ret [J].
Chiariello, M ;
Visconti, R ;
Carlomagno, F ;
Melillo, RM ;
Bucci, C ;
de Franciscis, V ;
Fox, GM ;
Jing, SQ ;
Coso, OA ;
Gutkind, JS ;
Fusco, A ;
Santoro, M .
ONCOGENE, 1998, 16 (19) :2435-2445